OncoMatch/Clinical Trials/NCT05263284
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
Is NCT05263284 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including 8-Chloroadenosine and Venetoclax for acute myeloid leukemia.
Treatment: 8-Chloroadenosine · Venetoclax — This phase I trial tests the safety, side effects, and best dose of a new 8-chloroadenosine in combination with venetoclax in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory). 8-Chloroadenosine may help block the formation of growths that may become cancer. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving 8-chloroadenosine in combination with venetoclax may help prevent the disease from coming back in patients with acute myeloid leukemia.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: salvage therapy — relapsed AML
Relapsed AML: Failed at least 1 line of salvage therapy
Must have received: induction chemotherapy — AML evolving from MDS or myeloproliferative disorder
AML evolving from myelodysplastic syndrome (MDS) or myeloproliferative disorder who have failed hypomethylating agents (HMA) or induction chemotherapy
Must have received: hypomethylating agent — AML evolving from MDS or myeloproliferative disorder
AML evolving from myelodysplastic syndrome (MDS) or myeloproliferative disorder who have failed hypomethylating agents (HMA) or induction chemotherapy
Lab requirements
Blood counts
White blood cell (WBC) <= 25 x 10^9/L prior to initiation of venetoclax
Kidney function
Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula
Liver function
Total bilirubin <= 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease); AST <= 2.5 x ULN; ALT <= 2.5 x ULN
Cardiac function
QTc <= 480 ms
White blood cell (WBC) <= 25 x 10^9/L prior to initiation of venetoclax. Total bilirubin <= 1.5 X upper limit of normal (ULN) (unless has Gilbert's disease). Aspartate aminotransferase (AST) <= 2.5 x ULN. Alanine aminotransferase (ALT) <= 2.5 x ULN. Creatinine clearance of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula. QTc <= 480 ms.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify